|
WO1982001011A1
(en)
|
1980-09-24 |
1982-04-01 |
Corp Cetus |
Diagnostic method and probe
|
|
DE3381518D1
(de)
|
1982-01-22 |
1990-06-07 |
Cetus Corp |
Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
|
|
US4582788A
(en)
|
1982-01-22 |
1986-04-15 |
Cetus Corporation |
HLA typing method and cDNA probes used therein
|
|
US4683194A
(en)
|
1984-05-29 |
1987-07-28 |
Cetus Corporation |
Method for detection of polymorphic restriction sites and nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
CA1284931C
(en)
|
1986-03-13 |
1991-06-18 |
Henry A. Erlich |
Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
|
|
CA1338457C
(en)
|
1986-08-22 |
1996-07-16 |
Henry A. Erlich |
Purified thermostable enzyme
|
|
US5093330A
(en)
|
1987-06-15 |
1992-03-03 |
Ciba-Geigy Corporation |
Staurosporine derivatives substituted at methylamino nitrogen
|
|
US6605712B1
(en)
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
|
AU6703198A
(en)
|
1997-03-21 |
1998-10-20 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
|
EP1210428B1
(en)
|
1999-08-23 |
2015-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
KR100942863B1
(ko)
|
1999-08-24 |
2010-02-17 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
WO2006034075A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Osi Pharmaceuticals, Inc. |
(hydrazido) (amino) thiophene compounds
|
|
BRPI0516483A
(pt)
*
|
2004-10-15 |
2008-09-02 |
Bayer Pharmaceuticals Corp |
preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
|
|
NZ563193A
(en)
|
2005-05-09 |
2010-05-28 |
Ono Pharmaceutical Co |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
ES2437327T3
(es)
|
2007-06-18 |
2014-01-10 |
Merck Sharp & Dohme B.V. |
Anticuerpos para el receptor PD-1 humano de muerte programada
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
|
BRPI0921392A2
(pt)
*
|
2008-12-05 |
2016-04-26 |
Abbott Lab |
inibidores quinase com perfil de segurança cyp aperfeiçoado
|
|
CN114835812A
(zh)
|
2008-12-09 |
2022-08-02 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
|
JP4965623B2
(ja)
|
2009-09-30 |
2012-07-04 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
|
|
WO2011082098A1
(en)
*
|
2009-12-30 |
2011-07-07 |
The Rockefeller University |
Lysine and arginine methyltransferase inhibitors for treating cancer
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
US8895607B2
(en)
*
|
2011-07-15 |
2014-11-25 |
The University Of Montana |
Inhibitors of the amino acid transporters ASCT1 and ASCT2
|
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
EA036814B9
(ru)
|
2011-11-28 |
2021-12-27 |
Мерк Патент Гмбх |
Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение
|
|
SG11201407190TA
(en)
|
2012-05-15 |
2014-12-30 |
Bristol Myers Squibb Co |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
EP3698809A1
(en)
|
2012-07-31 |
2020-08-26 |
The Brigham & Women's Hospital, Inc. |
Modulation of the immune response using agents binding tim-3 and ceacam-1
|
|
WO2014139388A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
NZ711355A
(en)
|
2013-03-15 |
2020-06-26 |
Glaxosmithkline Ip Dev Ltd |
Anti-lag-3 binding proteins
|
|
EP3656398A1
(en)
|
2013-09-11 |
2020-05-27 |
MedImmune Limited |
Anti-b7-h1 antibodies for treating tumors
|
|
TW201605857A
(zh)
*
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Ｃｄｋ８之醫療性抑制劑及其用途
|
|
CA2941693A1
(en)
|
2014-03-07 |
2015-09-11 |
University Health Network |
Methods and compositions for detection of targets involved in cancer metastasis
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
WO2016040527A1
(en)
*
|
2014-09-09 |
2016-03-17 |
Vanderbilt University |
Metabolism probes for therapy and diagnosis
|
|
DK4019019T3
(da)
*
|
2016-05-20 |
2024-05-06 |
Biohaven Therapeutics Ltd |
Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling
|
|
WO2018107173A1
(en)
|
2016-12-09 |
2018-06-14 |
Vanderbilt University |
Glutamine transport inhibitors and methods for treating cancer
|
|
TW202417417A
(zh)
*
|
2017-04-06 |
2024-05-01 |
美商富曼西公司 |
殺真菌之噁二唑
|
|
CN109369554B
(zh)
*
|
2018-10-18 |
2022-06-17 |
中国药科大学 |
一种含有异羟肟酸的取代杂环类化合物及其制备方法和用途
|